Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Macrophage interferon regulatory factor 4 deletion ameliorates aristolochic acid nephropathy via reduced migration and increased apoptosis
Kensuke Sasaki, Andrew S. Terker, Jiaqi Tang, Shirong Cao, Juan Pablo Arroyo, Aolei Niu, Suwan Wang, Xiaofeng Fan, Yahua Zhang, Stephanie R. Bennett, Ming-zhi Zhang, Raymond C. Harris
Kensuke Sasaki, Andrew S. Terker, Jiaqi Tang, Shirong Cao, Juan Pablo Arroyo, Aolei Niu, Suwan Wang, Xiaofeng Fan, Yahua Zhang, Stephanie R. Bennett, Ming-zhi Zhang, Raymond C. Harris
View: Text | PDF
Research Article Nephrology

Macrophage interferon regulatory factor 4 deletion ameliorates aristolochic acid nephropathy via reduced migration and increased apoptosis

  • Text
  • PDF
Abstract

Aristolochic acid (AA) is the causative nephrotoxic alkaloid in AA nephropathy, which results in a tubulointerstitial fibrosis. AA causes direct proximal tubule damage as well as an influx of macrophages, although the role of macrophages in pathogenesis is poorly understood. Here, we demonstrate that AA directly stimulates migration, inflammation, and ROS production in macrophages ex vivo. Cells lacking interferon regulatory factor 4 (IRF4), a known regulator of macrophage migration and phenotype, had a reduced migratory response, though effects on ROS production and inflammation were preserved or increased relative to WT cells. Macrophage-specific IRF4-knockout mice were protected from both acute and chronic kidney effects of AA administration based on functional and histological analysis. Renal macrophages from kidneys of AA-treated macrophage-specific IRF4-knockout mice demonstrated increased apoptosis and ROS production compared with WT controls, indicating that AA directly polarizes macrophages to a promigratory and proinflammatory phenotype. However, knockout mice had reduced renal macrophage abundance following AA administration. While macrophages lacking IRF4 can adopt a proinflammatory phenotype upon AA exposure, their inability to migrate to the kidney and increased rates of apoptosis upon infiltration provide protection from AA in vivo. These results provide evidence of direct AA effects on macrophages in AA nephropathy and add to the growing body of evidence that supports a key role of IRF4 in modulating macrophage function in kidney injury.

Authors

Kensuke Sasaki, Andrew S. Terker, Jiaqi Tang, Shirong Cao, Juan Pablo Arroyo, Aolei Niu, Suwan Wang, Xiaofeng Fan, Yahua Zhang, Stephanie R. Bennett, Ming-zhi Zhang, Raymond C. Harris

×

Figure 2

Effects of AA administration on renal function and kidney injury.

Options: View larger image (or click on image) Download as PowerPoint
Effects of AA administration on renal function and kidney injury.
(A) Ex...
(A) Experimental protocol. Animals received i.p. injections of AA (4mg/kg) every other day and were euthanized either at day 3 or day 8 after initial AA injection. (B) Total kidney mRNA abundance of Kim-1 at baseline and on days 3 and 8 of AA administration in WT control and macrophage IRF4–/– mice. (C) Kim-1 renal epithelial protein expression on days 3 and 8 of the AA administration protocol in WT control and macrophage IRF4–/– animals. Five fields of each kidney section were randomly selected, and the ratios of DAB-positive area to total areas in each field were counted in each high-power field using ImageJ software. (D) Plasma BUN following AA administration in WT and macrophage IRF4–/– animals. (E and F) Effects of AA administration on kidney macrophage (E) apoptosis and (F) ROS production in WT control and macrophage IRF4–/– animals on day 8 of the AA protocol. For A and B, n = 4 for baseline and day 3 time points for both genotypes; n = 5 for the day 8 time point for control mice and 4 for macrophage IRF4–/– mice. For C, n = 4 per group for day 3 and 5 per group for day 8. For D, n = 5 per group. For E and F, n = 3 for WT control and 5 for macrophage IRF4–/– mice. *P < 0.05 by 2-way ANOVA with repeated measures followed by Šidák post hoc test to compare within or between genotype differences at indicated time points. †P < 0.05 for interaction of genotype and treatment variables by 2-way ANOVA. ††P < 0.05 for interaction by 2-way ANOVA with repeated measures. **P < 0.05 by unpaired Student’s t test. Mϕ, macrophage. Note that all animals were treated with AA except baseline groups in B.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts